Navigation Links
Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals
Date:12/22/2009

and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. Pixantrone also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

The PIX 301 EXTEND phase III clinical trial in relapsed or refractory aggressive NHL was a single-agent trial of pixantrone in patients who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The results of the trial showed that patients randomized to treatment with pixantrone achieved a significantly higher rate of confirmed and unconfirmed complete response, had a significantly increased overall response rate and experience a significant improvement in median progression free survival compared to patients treated with standard chemotherapy. The most common (incidence greater than or equal to 10%) grade 3-4 adverse events reported for pixantrone-treated subjects across the studies were neutropenia and leucopenia.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site,

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
2. Dennis Winger Joins Nektar Therapeutics Board of Directors
3. Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
4. Oxford BioTherapeutics Appoints Michael Moore as Chairman
5. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
6. Cell Therapeutics, Inc. (CTI) to Present at 21st Annual Piper Jaffray Health Care Conference
7. Pearl Therapeutics Appoints Howie Rosen to Board of Directors
8. Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
9. Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
10. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
11. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready for business, ... Innovation Center @3401 , a collaborative effort of Drexel ... to help attract and nurture start-up businesses in the region, ... , The Innovation Center @3401 (ic@3401), which is located ... new home of DreamIt Ventures and Point.io ...
(Date:7/29/2014)... July 29, 2014  Sigma-Aldrich Corporation (NASDAQ: ... use, increased its investment in Green Chemistry and donated ... world last year, the Company announced Monday in its ... Changed the World? The report comes ... for being a responsible corporate citizen, including recognition for ...
(Date:7/29/2014)... Quorum Review IRB, the industry ... accreditation by the International Association of Six ... Sigma Deployment Program. The citation recognizes robust organizational ... Quorum’s Lean Six Sigma program was evaluated by ... The designation is a public statement of excellence ...
(Date:7/29/2014)... Bryan, TX (PRWEB) July 29, 2014 ... of autonomous modular cleanrooms, today announced a new leadership ... in the United States and abroad. , Maik ... named as the company’s President charged with leading the ... , “As we enter this stage of development and ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2
... , , COLUMBIA, Md., Dec. 16 Martek ... for the fourth quarter and fiscal year ended October 31, 2009. ... $90.4 million in the fourth quarter of fiscal 2008. Net income ... quarter of fiscal 2009, a 5% increase compared with $10.5 million, ...
... , , LAS VEGAS, Dec. 16 Cord Blood America, Inc. ... company ( http://www.cordblood-america.com ) focused on bringing the life saving ... and internationally, said today that it has reduced its debt by ... of 2009 and total debt eliminated for the year now tops ...
... , , ... Inc. (Nasdaq: SQNM ), today announced the appointment of Dr. ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) , Kenneth F. Buechler, ... From 1988 to 1994, Dr. Buechler was Biosite,s director of chemistry. ...
Cached Biology Technology:Martek Announces Fourth Quarter and FY 2009 Financial Results 2Martek Announces Fourth Quarter and FY 2009 Financial Results 3Martek Announces Fourth Quarter and FY 2009 Financial Results 4Martek Announces Fourth Quarter and FY 2009 Financial Results 5Martek Announces Fourth Quarter and FY 2009 Financial Results 6Martek Announces Fourth Quarter and FY 2009 Financial Results 7Martek Announces Fourth Quarter and FY 2009 Financial Results 8Martek Announces Fourth Quarter and FY 2009 Financial Results 9Martek Announces Fourth Quarter and FY 2009 Financial Results 10Martek Announces Fourth Quarter and FY 2009 Financial Results 11Martek Announces Fourth Quarter and FY 2009 Financial Results 12Martek Announces Fourth Quarter and FY 2009 Financial Results 13Martek Announces Fourth Quarter and FY 2009 Financial Results 14Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3
(Date:7/29/2014)... fascinating journey to the edge of science, Clment Vidal ... The Beginning and the End: Does our universe have ... Are we alone in the universe? What is the ... Grounded in science and committed to philosophical rigor, the ... intelligent life is not an accident, but may well ...
(Date:7/29/2014)... comes to technology, healthcare is usually one of the last industries ... comes to wearables, healthcare is trying to move ahead of the ... and its wearable cousins is less than mature, these devices are ... in the hospital for a major procedure or for personal use ... mind, InformationWeek editor Rodney Brown set out to ...
(Date:7/29/2014)... personal genetics company, has received from the National ... for a two-year project to support the further ... for genetic discovery. , Specifically, the grant ... of web-based surveys to improve the company,s ability ... of survey tools to support the collection of ...
Breaking Biology News(10 mins):Book: 'The Beginning and the End' 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3
... found that the number of pests and disease outbreaks in ... The review "The consequences of Tree Pests and ... Southampton, Cambridge, Oxford and St Andrews is published today (15 ... shows that the experience of widespread death of trees, similar ...
... Clinic Lerner Research Institute have discovered recent genetic mutations ... of malaria annuallychanges that may render tens of millions ... infection. Peter A. Zimmerman, professor of international health, ... of Medicine, and David Serre, a scientific staff member ...
... , Nov. 14, 2013 Wake Forest Baptist Medical ... first-of-its-kind strategic affiliation agreement in the Triad with Cornerstone ... Cornerstone Health Enablement Strategic Solutions, LLC (CHESS). ... both partners for new models of health care delivery ...
Cached Biology News:Rising concerns over tree pests and diseases 2Vivax malaria may be evolving around natural defense 2Vivax malaria may be evolving around natural defense 3Wake Forest Baptist Medical Center and Cornerstone Health Care Join in Unique Affiliation 2Wake Forest Baptist Medical Center and Cornerstone Health Care Join in Unique Affiliation 3
... The Bio-Plex suspension array system, 100-240 V, ... for simultaneous quantitative analysis of up to ... microplate well. The suspension array is composed ... each of which may be conjugated with ...
...
... Disposable. Virgin, optically clear polystyrene with ... alphanumeric coordinates for cell counting. 100% ... is a new product number, created ... If showing no availability yet, please ...
... 100 IS System is a compact analysis system ... lasers, optics, fluidics, a controller, advanced digital signal ... compact lab analysis system includes the Luminex 100, ... has a DMF file at the FDA, and ...
Biology Products: